ClinicalTrials.gg
RecruitingNCT07619820Updated Jul 7, 2026

A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

A Phase 1 interventional study of CSL300 and Placebo in End Stage Kidney Disease (ESKD), sponsored by CSL Behring. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Kidney Failure, Chronic with a site in China — 28 open to participants now, 36 under way, 1 of them phase 3. Kidney Failure, Chronic · China.

Planned enrollment
78th of 83
24 · median 150
Started
2026
with 5 others
Phase 1
6 of 114
2 open now
Primary completion
2027-08
later than 26 of 35 live
Registered
109th of 114
by date

Among the 114 studies in Kidney Failure, Chronic with a site in China, this one is the 78th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 26 of the 35 other live ones, and was the 109th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

28 of the 114 studies in Kidney Failure, Chronic with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Kidney Failure, Chronic with a site in China, or all of them as a file.
02

Study summary

This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in Chinese participants with end stage kidney disease (ESKD) undergoing dialysis.

03

Conditions studied

  • End Stage Kidney Disease (ESKD)

Keywords

  • High-sensitivity C-reactive protein
  • High-density lipoprotein cholesterol
  • Interleukin-6
  • Humanized Monoclonal antibody
  • Atherosclerotic cardiovascular disease
  • Diabetes mellitus
  • Systemic inflammation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants has provided written and is willing and able to adhere to all protocol requirements.
  • Aged 18 or older, inclusive, at the time of providing written informed consent.
  • Diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks before Screening.

Exclusion criteria

Exclusion Criteria:

  • Exclusion related to risk of infection: concomitant use of systemic agents, primary immunodeficiency, positive test for active tuberculosis (TB), history of latent TB without completion of full course of prophylactic treatment, evidence of infection during Screening, seropositivity for surface antigen or positive hepatitis B virus (HBV) DNA during Screening, seropositivity for virus ribonucleic acid during Screening, diagnosis of active infection, history of / OR current invasive fungal infection OR other opportunistic infection OR recurrent cellulitis (defined as 2 or more episodes in the year prior to screening), administration of a within 6 weeks of start of Screening, presence of urinary catheter, or evidence of wet gangrene or nonhealing ulcers.
  • Exclusion related to laboratory abnormalities: abnormal liver function tests, neutropenia, thrombocytopenia, or significant anemia.
  • Exclusion related to medical history: any life-threatening disease expected to result in death within 12 months (other than cardiovascular disease), evidence of active hepatic disease and / or moderate or severe hepatic impairment, recent unplanned hospitalization (\< 30 days) prior to Screening, recent (\< 3 months) major surgery or planned major surgery known at the time of Screening, poorly controlled hypertension, a present or previous (\< 5 years) except for basal cell carcinoma, fully excised squamous cell carcinoma of the skin, or nonrecurrent (\< 5 years of Screening) cervical carcinoma in situ, active or recent (\< 30 days of Screening) clinically severe bleeding, a scheduled kidney transplant within 6 months of Screening, a history of anaphylaxis or to CSL300 or any constituents of the product, or a history of demyelinating disorders.
  • Exclusion related to risk of gastrointestinal perforation: a history of GI perforation, inflammatory bowel disease (except fully excised ulcerative colitis), or peptic ulcer disease (\< 12 months before Screening), a history of diverticular disease or diverticulitis (except if disease has been fully excised). An incidental finding of diverticulosis (presence of small diverticula) and no history of symptoms, complications, or any episodes requiring treatment may be eligible for the study based on investigator's judgment. However, any history of complications, inflammation, or infection suggestive of diverticulitis or diverticular disease is exclusionary, inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis except if fully excised, or prior gastric bypass surgery.
  • Exclusion related to treatment compliance: evidence of inadequate dialysis, unwillingness or inability to comply with study procedures, a history of noncompliance with medical treatments, or ongoing alcohol or illicit substance abuse.
  • Current or recent participation in research study involving an experimental agent \< 3 months of Screening.
  • Pregnant, breastfeeding, or unwillingness to practice adequate during the study and for 5 months after the last dose of product.
  • The presence of any condition that in the opinion of the Investigator would (1) compromise the safety of the participant in case of participation in the study, (2) compromise the quality of the data, and / or (3) limit the of the participant to \< 1 year.
  • The Sponsor determines that the participant is no longer needed for participation in study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    CSL300 (Clazakizumab)

    Participants will receive CSL300 once every 4 weeks (Q4W) as a slow intravenous (IV) bolus, for a total of 20 weeks during the Treatment Period.

    Biological: CSL300

  • Placebo comparator
    Placebo

    Participants will receive a placebo matching to CSL300 Q4W as a slow IV bolus, for a total of 20 weeks during the treatment period.

    Other: Placebo

Interventions

  • BiologicalCSL300

    CSL300 is a humanized anti-interleukin 6 (anti-IL-6) monoclonal antibody (mAb).

  • OtherPlacebo

    Placebo is a solution for injection matching the excipient content and concentration of the CSL300 product, minus the active ingredient.

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time (AUC) Curve of CSL300 Over 1 Dosing Interval After Multiple Doses (AUC0-tau,MD)

    Time frame: Day 85 up to Day 113

  2. Trough Concentration at Steady State (Ctrough,ss)

    Time frame: Up to Day 141

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interests (AESIs)

    The following adverse events (AEs) are defined as AESIs: relevant infections (tuberculosis, herpes simplex virus, herpes zoster, human papillomavirus, human immunodeficiency virus, hepatitis B, hepatitis C, and invasive fungal infections), and demyelinating disorders.

    Time frame: Up to Day 225 (End of Study [EoS])

  2. Percentage of Participants With TEAEs, SAEs, and AESIs

    The following AEs are defined as AESIs: relevant infections (tuberculosis, herpes simplex virus, herpes zoster, human papillomavirus, human immunodeficiency virus, hepatitis B, hepatitis C, and invasive fungal infections), and demyelinating disorders.

    Time frame: Up to Day 225 (EoS)

  3. Percentage of Participants With a Clinically Significant Change From Baseline in Laboratory Test Results

    Laboratory assessments will include hematology parameters such as white blood cells (leukocytes), neutrophils, and platelets; chemistry evaluations including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin; a lipid panel comprising total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides; and immunogenicity testing.

    Time frame: At Baseline and up to Day 225 (EoS)

  4. Number of Participants With Antidrug Antibodies

    The detection of antibodies to CSL300 will be performed using a validated immunoassay method.

    Time frame: At Days 1, 29, 85, and 169

  5. Maximum Observed Concentration (Cmax) of CSL300

    Time frame: Up to Day 169

  6. Area Under the Concentration-Time Curve From Time 0 to Day 28 (AUC0-28d) of CSL300

    Time frame: Up to Day 28

  7. Trough Concentration (Ctrough) of CSL300

    Time frame: Up to Day 141

  8. Time to Reach Cmax (Tmax) of CSL300

    Time frame: Up to Day 85

  9. Change From Baseline on log-scale High-Sensitivity C-reactive Protein (hs-CRP)

    Time frame: At Baseline, Week 12, and Week 24

  10. Plasma Interleukin-6 (IL-6) Free and Total Levels

    Time frame: At Weeks 12 and 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 14 months after the start.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 14 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 2, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07619820
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jun 17, 2026
Primary completion
Aug 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jul 7, 2026

Study contacts

Trial Registration Coordinator
Contact
clinicaltrials@cslbehring.com
+16108784697

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion